Question 1

What is the catalog number for Phos-INS R (Y1162/3)/IGF-IR (Y1135/6) Affinity Purified PAb?

Accepted Answer

The catalog number for Phos-INS R (Y1162/3)/IGF-IR (Y1135/6) Affinity Purified PAb is AF2507.

Question 2

What sizes are available for Phos-INS R (Y1162/3)/IGF-IR (Y1135/6) Affinity Purified PAb?

Accepted Answer

Phos-INS R (Y1162/3)/IGF-IR (Y1135/6) Affinity Purified PAb is available in the following size(s): 50 µg.

Question 3

Is Phos-INS R (Y1162/3)/IGF-IR (Y1135/6) Affinity Purified PAb in stock?

Accepted Answer

Phos-INS R (Y1162/3)/IGF-IR (Y1135/6) Affinity Purified PAb is currently made to order / not held in immediate stock. Contact us for lead time.

Question 4

Can this product be used for co-immunoprecipitation (Co-IP)?

Accepted Answer

Suitability for Co-IP depends on the specific antibody and is noted under validated applications on the datasheet. If it isn’t listed, contact our technical support team for guidance based on your target and sample type.

Question 5

Is this kit compatible with automated liquid handling platforms?

Accepted Answer

Automation compatibility varies by kit and isn’t always listed on the datasheet. Contact our technical support team with details of your platform so we can confirm with the manufacturer.

Question 6

What applications has this product been validated for?

Accepted Answer

Validated applications such as WB, ELISA, IHC, ICC, or FC are listed on the product datasheet. If you need application-specific validation data before ordering, contact our technical support team with the catalogue number.

Phos-INS R (Y1162/3)/IGF-IR (Y1135/6) Affinity Purified PAb

Product Specifications

Frequently Asked Questions

Explore Other Products

Parkin Recombinant Rabbit Monoclonal Antibody [JF82-09]

CD284 / TLR4 (TLR4/230), CF647 conjugate, 0.1mg/mL

Human IgG Immunoglobulin (IG217), CF740 conjugate, 0.1mg/mL

Nucleophosmin (Acute Myeloid Leukemia Marker) (NPM1/3286), 0.2mg/mL

MMP9 (MMP9/2025R), 1mg/mL

eIF2A Recombinant Rabbit Monoclonal Antibody [JE58-18]